Military Outreach and Veterans Engagement (MOVE), launched in 2019 by the North Carolina Biotechnology Center, has joined the U.S. Department of Defense’s SkillBridge initiative. SkillBridge provides ...

Military Outreach and Veterans Engagement (MOVE), launched in 2019 by the North Carolina Biotechnology Center, has joined the U.S. Department of Defense’s SkillBridge initiative. SkillBridge provides ...

If you’re interested in participating in a clinical trial to solve some of the riddles of COVID-19, LabCorp can help you make that connection. The Burlington-based corporation’s Covance drug ...

From eating utensils to coffee pods, many of us use plastic products daily. PlantSwitch has a mission to make these items more sustainable by replacing traditional petroleum-based plastics with ...

Losing a job due to layoff is all too common in today's world, and finding your next opportunity is a full-time job. Those of us who are professional scientists who want to stay in North Carolina are ...

Bluebird bio, a Massachusetts-based gene and cell therapy company with operations in North Carolina, will sell its Durham biomanufacturing plant to National Resilience for $110 million as part of a ...

This summer, five community college instructors had the opportunity to learn what it is really like to work at a biotech company or institution through the Biomedical Emerging Technology Applications ...

Stem cells have the potential to unlock solutions to a wide array of medical problems. In recent years, stem cells have been incorporated into innovative and successful therapies for cancer and HIV.

Vast Therapeutics is celebrating the new year with Series A funding in excess of $15 million from Shionogi & Co., Ltd. (TYO: 4507) of Japan and a $300,000 award from the Cystic Fibrosis Foundation.

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

This white paper explains how these strengths work together to create the optimal destination for biomanufacturing companies to flourish.

Brii said it agreed to purchase the assets from VBI Vaccines Inc. and its creditors for $18 million. The deal gives Brii full access to the remaining IP, patents and materials related to BRII-179, an ...